Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Stock Picked Up by Analysts at HC Wainwright

Equities research analysts at HC Wainwright started coverage on shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set a “buy” rating on the stock.

Several other analysts also recently commented on LABT. Wall Street Zen upgraded shares of Lakewood-Amedex Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. Weiss Ratings upgraded shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Lakewood-Amedex Biotherapeutics currently has a consensus rating of “Hold”.

Lakewood-Amedex Biotherapeutics Stock Performance

LABT traded down $0.00 during trading on Wednesday, hitting $0.29. The company’s stock had a trading volume of 4,841,907 shares, compared to its average volume of 1,731,883. The stock has a market cap of $675,450.00 and a price-to-earnings ratio of -0.06. Lakewood-Amedex Biotherapeutics has a one year low of $0.24 and a one year high of $98.20. The stock has a 50 day moving average price of $1.51.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last announced its quarterly earnings data on Friday, August 14th. The company reported ($2.75) EPS for the quarter. Analysts expect that Lakewood-Amedex Biotherapeutics will post 4.96 earnings per share for the current fiscal year.

Lakewood-Amedex Biotherapeutics Company Profile

Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.

The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.

Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.